WeTrials
Recruiting

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

What is this study?

This study tests a new medication called axatilimab combined with a standard cancer drug called olaparib. Researchers want to see if this combination is safe and helps treat advanced breast cancer linked to specific genetic changes like BRCA1, BRCA2, or PALB2.

Who can participate?

You may be eligible if you are 18 or older with advanced HER2-negative breast cancer and have a confirmed gene mutation in BRCA1, BRCA2, or PALB2. There are limits on previous treatments, and you cannot have stopped responding to PARP inhibitor drugs in the past.

What will happen?

Participants will receive both study drugs and will be closely monitored by the medical team for safety and side effects. You will need regular check-ups and imaging scans to see how your body responds to the treatment.

Where and when?

The study is currently recruiting patients and takes place in select locations including Boston, Massachusetts, and Rochester, Minnesota.

Key Points
  • 1Tests axatilimab combined with standard olaparib for specific breast cancers.
  • 2Open to adults with HER2-negative breast cancer and BRCA1, BRCA2, or PALB2 gene mutations.
  • 3Currently active and recruiting patients in Massachusetts and Minnesota.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast CancerBRCA1 MutationBRCA2 Mutation

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.